Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
[15] If a scheduled injection is missed, the patient should administer the dose as soon as remembered unless it is within 24 hours of the next scheduled dose, in which case the missed dose is omitted to prevent overlap
Always, always speak with a qualified medical professional before considering any experimental compound
GHK naturally occurs in human plasma at approximately 200 ng/mL in young adults, declining significantly with age (PMID 29986520)
This is the use case where AOD-9604 has the most appeal but potentially the least clinical data to support it
AOD-9604 is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications